Sartorius (OTCMKTS:SARTF) and Biomerica (NASDAQ:BMRA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Ratings

This is a breakdown of current ratings and target prices for Sartorius and Biomerica, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sartorius 1 0 0 0 1.00
Biomerica 0 0 1 0 3.00

Biomerica has a consensus target price of $7.50, indicating a potential upside of 145.10%. Given Biomerica’s stronger consensus rating and higher probable upside, analysts clearly believe Biomerica is more favorable than Sartorius.

Institutional and Insider Ownership

1.5% of Biomerica shares are owned by institutional investors. 26.8% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Sartorius has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Biomerica has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Valuation & Earnings

This table compares Sartorius and Biomerica’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sartorius $1.59 billion 3.17 $129.67 million N/A N/A
Biomerica $5.56 million 4.97 -$1.46 million ($0.17) -18.00

Sartorius has higher revenue and earnings than Biomerica.

Profitability

This table compares Sartorius and Biomerica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sartorius 9.44% 21.72% 7.63%
Biomerica -31.75% -41.73% -34.79%

Summary

Sartorius beats Biomerica on 7 of the 13 factors compared between the two stocks.

Sartorius Company Profile

There is no company description available for Sartorius AG.

Biomerica Company Profile

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.